Stocksigma LogoStocksigma Logo

Concord Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

■ Revenue: 2,075 (+102.0% YoY | -0.9% QoQ) ■ EBITDA: 236 (+115.7% YoY | +3.6% QoQ) ■ EBITDA Margin (%): 11.4 (+73 bps YoY | +50 bps QoQ) ■ PAT: 110

Concord Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

Concord Drugs Ltd · Outcome · 13 Nov 2026, 12:24 am

Concord Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 2,075 (+102.0% YoY | -0.9% QoQ) ■ EBITDA: 236 (+115.7% YoY | +3.6% QoQ) ■ EBITDA Margin (%): 11.4 (+73 bps YoY | +50 bps QoQ) ■ PAT: 110 (+471.0% YoY | -1.5% QoQ) ■ EPS (INR): 0.83 (+336.8% YoY | -2.4% QoQ)

Original exchange filing (PDF)

More announcements from Concord Drugs Ltd

All Concord Drugs Ltd announcements